Citations

Showing 10 of 108119 citations.

Applicant Perceptions Regarding the 2020 to 2021 Virtual Ophthalmology Residency Interview and Match Season
Shah, Saumya M. , Tooley, Andrea A. , Barkmeier, Andrew J. , Dalvin, Lauren A.

Mayo Clinic

Journal of Academic Ophthalmology | November 10, 2021 | Volume: 13 | Issue: 02 | Pages: e144-e150

10.1055/s-0041-1735952 | PMID 37388847 Get It

Abstract Background The coronavirus disease 2019 pandemic has significantly impacted medical education, notably the mandate for all residency programs to implement virtual (rather than in-person) residency interviews. Understanding residency applicants' perceptions and approach to this novel virtual interview season will be beneficial as potential future interview formats are considered. Objective The aim of this study was to examine perceptions of the 2020 to 2021 ophthalmology residency match applicants regarding the virtual interview season prior to the start of the interview season. Patients and Methods Ophthalmology residency applicants during the 2020 to 2021 cycle were invited to complete the survey between October 20 and 29, 2020. Respondent demographic information, perceived importance of various application details in a normal versus virtual interview season, strengths and limitations of virtual interviews, and preferences for optimal virtual interview format were obtained. Results There were 337 survey respondents, with at least 50% of the survey completed by 190 applicants (56%). Of these, 73% of respondents applied to more than 60 ophthalmology residency programs, and 78% felt that the evaluation of candidates would be impacted by the virtual interview format. Regardless of interview format, United States Medical Licensing Examination Step 1 score and letters of recommendation were perceived to be the two most important factors related to matching at an applicant's top ranked programs. The primary limitation of a virtual interview season was the inability to experience a program's culture in person, while largest strength was cost savings. Conclusion The ophthalmology residency match is a competitive process made potentially more complex by a novel virtual interview format. A detailed postcycle analysis will be important to optimize future interview seasons.
Ultrasonographic Measurement of Elbow Varus Laxity With a Sequential Injury Model of the Lateral Collateral Ligament–Capsular Complex
Rotman, Dani , Liévano, Jorge Rojas , O’Driscoll, Shawn W. , Kwak, Jae-Man, Fitzsimmons, James S. , O'Driscoll, Shawn W., Fitzsimmons, James S , Kwak, Jae‐Man , Lievano, Jorge Rojas

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 10, 2021 | Volume: 9 | Issue: 11 | Pages: No page available

10.1177/23259671211048941 | PMID 34778473 Get It

Background: There is no consensus how to determine the varus laxity due to the LCL injury using the ultrasonography. There is a risk of lateral collateral ligament injury during or after arthroscopic extensor carpi radialis brevis release for tennis elbow. The equator of the radial head has been suggested as a landmark for the safe zone to not increase this risk; however, the safe zone from the intra-articular space has not been established. Hypothesis: Increased elbow varus laxity due to lateral collateral ligament–capsular complex (LCL-cc) injury could be assessed reliably via ultrasound. Study Design: Descriptive laboratory study. Methods: Eight cadaveric elbows were evaluated using a custom-made machine allowing passive elbow flexion under gravity varus stress. The radiocapitellar joint (RCJ) space was measured via ultrasound at 30° and 90° of flexion during 4 stages: intact elbow (stage 0), release of the anterior one-third of the LCL-cc (stage 1), release of the anterior two-thirds (stage 2), and release of the entire LCL-cc (stage 3). Two observers conducted the measurements separately, and the mean RCJ space in the 3 LCL-cc injury models (stages 1-3) at both flexion angles was compared with that of the intact elbow (stage 0). We also compared the measurements at 30° versus 90° of flexion. Results: At 30° of elbow flexion, the RCJ space increased 2 mm between stages 0 and 2 (95% confidence interval [CI], 1-3 mm; P < .01) and 4 mm between stages 0 and 3 (95% CI, 2-5 mm; P < .01). At 90° of elbow flexion, the RCJ space increased 1 mm between stages 0 and 2 (95% CI, 1-2 mm; P < .01) and 2 mm between stages 0 and 3 (95% CI, 2-3 mm; P < .01). Conclusion: Elbow varus laxity under gravity stress can be reliably assessed via ultrasound by measuring the RCJ space. Clinical Relevance: Because ultrasonographic measurement of the RCJ space can distinguish the increasing varus laxity seen with release of two-thirds or more of the LCL-cc, the anterior one-third of the LCL-cc, based on the diameter of the radial head, can be considered the safe zone in arthroscopic extensor carpi radialis brevis release for tennis elbow.
Hospital medicine team perception of diversity and inclusion at work
Pagali, Sandeep R. , Kiliaki, Shangwe A. , Rizvi, Syed Ahsan, Pagali, Sandeep , Rizvi, Syed Ahsan

Mayo Clinic

Hospital Practice | November 10, 2021 | Volume: 49 | Issue: 5 | Pages: 376-378

10.1080/21548331.2021.2003672 | PMID 34755581 Get It

Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport
Ariagno, Sydney , Thorvilson, Megan J. , Andersen, Lezlie H., Collura, Christopher A. , Thorvilson, Megan, Andersen, Lezlie, Collura, Christopher, Ariagno, Sydney

Mayo Clinic

Journal of Palliative Medicine | November 10, 2021 | Volume: 25 | Issue: 5 | Pages: 840-843

10.1089/jpm.2021.0383 | PMID 34756099 Get It

Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity. Although caffeine has long been used for apnea of prematurity, its use has not yet been reported for infants with T18. Here we describe an infant with T18 receiving comfort-focused care and palliative transport home. Of utmost importance to her family was enabling the patient to spend time at home before her death. However, immediately before transport, she developed severe central apnea, raising concern that she may not survive the transfer. Caffeine was trialed in the hopes of reducing central apnea events. Its use was successful and facilitated safe transport, allowing the patient to uneventfully transition home, where she spent several meaningful weeks with her family before her death.
IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model
Zhang, Cuiping , Delawary, Mina, Huang, Peng , Korchak, Jennifer A. , Suda, Koji, Zubair, Abba C. , Zubair, Abba C

Mayo Clinic

Cells | November 10, 2021 | Volume: 10 | Issue: 11 | Pages: 3101

10.3390/cells10113101 | PMID 34831324 Get It

Mesenchymal stem cells (MSCs) are used in various studies to induce immunomodulatory effects in clinical conditions associated with immune dysregulation such as graft versus host disease (GvHD). However, most of these clinical trials failed to go beyond early phase 2 studies because of limited efficacy. Various methods have been assessed to increase the potency of MSCs. IL-10 is an anti-inflammatory cytokine that is known to modulate immune responses in GvHD. In this study, we evaluated the feasibility of transfecting IL-10 mRNA to enhance MSC therapeutic potential. IL-10 mRNA engineered MSCs (eMSCs-IL10) maintained high levels of IL-10 expression even after freezing and thawing. IL-10 mRNA transfection did not appear to alter MSC intrinsic characteristics. eMSCs-IL10 significantly suppressed T cell proliferation relative to naïve MSCs in vitro. In a mouse model for GvHD, eMSCs-IL10 induced a decrease in plasma level of potent pro-inflammatory cytokines and inhibited CD4+ and CD8+ T cell proliferation in the spleen. In summary, our studies demonstrate the feasibility of potentiating MSCs to enhance their immunomodulatory effects by IL-10 mRNA transfection. The use of non-viral transfection may generate a safe and potent MSC product for treatment of clinical conditions associated with immune dysregulation such as GvHD.
Diagnosis of Hypersensitivity Pneumonitis
Beasley, Mary Beth , Colby, Thomas V. , Lynch, David, Müller, Néstor L. , Yang, Soo-Ryum , Churg, Andrew , Pérez, Evans R. Fernández , Travis, William D.

Mayo Clinic

American Journal of Surgical Pathology | November 10, 2021 | Volume: 46 | Issue: 4 | Pages: e71-e93

10.1097/pas.0000000000001827 | PMID 34753865 Get It

Assessment of lung biopsies for the diagnosis of hypersensitivity pneumonitis (HP) is one of the most difficult diagnostic problems for surgical pathologists. It is a form of interstitial lung disease resulting from an immune reaction provoked by an inhaled antigen in susceptible individuals. Although this definition sounds simple, in practice, the diagnosis of HP can be challenging. To address these issues, the American College of Chest Physicians (CHEST) has recently published a guideline for the diagnosis of HP. In this review, we will explore the multidisciplinary diagnostic evaluation of HP with a focus on the pathologic features as outlined in the CHEST guidelines. The histologic criteria are divided into 4 diagnostic categories: (1) Typical nonfibrotic HP or fibrotic HP; (2) Compatible with nonfibrotic HP or fibrotic HP; (3) Indeterminate for nonfibrotic or fibrotic HP; and (4) Alternative Diagnosis. It is important to emphasize that patterns 1 to 3 do not represent discrete histologic entities or pathologic diagnoses. Rather, these categories are meant to serve as a practical guide for organizing a complex set of overlapping histologic patterns into an integrated diagnostic framework for facilitating multidisciplinary discussion. High-resolution computed tomography features are also summarized, emphasizing how the correlation of lung biopsies with computed tomography findings can help to favor the diagnosis, particularly in cases where biopsies are not typical for HP. This review highlights details of the histologic spectrum of HP as well as the utility of different types of biopsies and bronchoalveolar lavage. We also emphasize the importance of multidisciplinary discussion and the complex differential diagnosis.
Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia
Ezzati, Ali , Jack, Clifford R. , Thompson, Paul M. , Harvey, Danielle , Truelove‐Hill, Monica , Sreepada, Lasya P , Initiative, the Alzheimer's Disease Neuroimaging, Lipton, Richard B., Jack, Clifford R , Thompson, Paul M , Harvey, Danielle J , Abdulkadir, Ahmed , Davatzikos, Christos , Initiative, the Alzheimer's Disease Neuroimaging, Lipton, Richard B.

Mayo Clinic

Alzheimer's & Dementia | November 10, 2021 | Volume: 17 | Issue: 11 | Pages: 1855-1867

10.1002/alz.12491 | PMID 34870371 Get It

AbstractWe aimed to evaluate the value of ATN biomarker classification system (amyloid beta [A], pathologic tau [T], and neurodegeneration [N]) for predicting conversion from mild cognitive impairment (MCI) to dementia. In a sample of people with MCI (n = 415) we assessed predictive performance of ATN classification using empirical knowledge‐based cut‐offs for each component of ATN and compared it to two data‐driven approaches, logistic regression and RUSBoost machine learning classifiers, which used continuous clinical or biomarker scores. In data‐driven approaches, we identified ATN features that distinguish normals from individuals with dementia and used them to classify persons with MCI into dementia‐like and normal groups. Both data‐driven classification methods performed better than the empirical cut‐offs for ATN biomarkers in predicting conversion to dementia. Classifiers that used clinical features performed as well as classifiers that used ATN biomarkers for prediction of progression to dementia. We discuss that data‐driven modeling approaches can improve our ability to predict disease progression and might have implications in future clinical trials.
Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words?
Meagher, Karen M. , Finn, Kelsey Stuttgen , Curtis, Susan , Borucki, Jack, Beck, Annika T., Cheema, Amal , Sharp, Richard R. , Stuttgen Finn, Kelsey, Curtis, Susan H , Cheema, Amal W, Sharp, Richard R , Meagher, Karen M , Stuttgen, Kelsey

Mayo Clinic

Clinical and Translational Science | November 10, 2021 | Volume: 15 | Issue: 3 | Pages: 721-731

10.1111/cts.13193 | PMID 34755460 Get It

AbstractAs pharmacogenomic (PGx) testing increases in popularity, lay concepts of drug‐gene interactions set the stage for shared decision making in precision medicine. Few studies explore what recipients of PGx results think is happening in their bodies when a drug‐gene interaction is discovered. To characterize biobank participants’ understanding of PGx research results, we conducted a focus group study, which took place after PGx variants conferring increased risk of dihydropyrimidine dehydrogenase (DPD) deficiency were disclosed to biobank contributors. DPD deficiency confers an increased risk of adverse reaction to commonly used cancer chemotherapeutics. Ten focus groups were conducted, ranging from two to eight participants. Fifty‐four individuals participated in focus groups. A framework approach was used for descriptive and explanatory analysis. Descriptive themes included participants’ efforts to make sense of PGx findings as they related to: (1) health implications, (2) drugs, and (3) genetics. Explanatory analysis supplied a functional framework of how participant word choices can perform different purposes in PGx communication. Results bear three main implications for PGx research‐related disclosure. First, participants’ use of various terms suggest participants generally understanding their PGx results, including how positive PGx results differ from positive disease susceptibility genetic results. Second, PGx disclosure in biobanking can involve participant conflation of drug‐gene interactions with allergies or other types of medical reactions. Third, the functional framework suggests a need to move beyond a deficit model of genetic literacy in PGx communication. Together, findings provide an initial evidence base for supporting bidirectional expert‐recipient PGx results communication.
Combined control of the fibroblast contractile program by YAP and TAZ
Link, Patrick A. , Choi, Kyoung Moo , Espinosa, Ana M. Diaz , Jones, Dakota L. , Gao, Ashley Y. , Haak, Andrew J. , Tschumperlin, Daniel J. , Diaz Espinosa, Ana M , Link, Patrick A

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | November 10, 2021 | Volume: 322 | Issue: 1 | Pages: L23-L32

10.1152/ajplung.00210.2021 | PMID 34755530 Get It

Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are transcription cofactors implicated in the contractile and profibrotic activation of fibroblasts. Fibroblast contractile function is important in alveologenesis and in lung wound healing and fibrosis. As paralogs, YAP and TAZ may have independent or redundant roles in regulating transcriptional programs and contractile function. Using IMR-90 lung fibroblasts, microarray analysis, and traction microscopy, we tested whether independent YAP or TAZ knockdown alone was sufficient to limit transcriptional activation and contraction in vitro. Our results demonstrate limited effects of knockdown of either YAP or TAZ alone, with more robust transcriptional and functional effects observed with combined knockdown, consistent with cooperation or redundancy of YAP and TAZ in transforming growth factor β1 (TGFβ1)-induced fibroblast activation and contractile force generation. The transcriptional responses to combined YAP/TAZ knockdown were focused on a relatively small subset of genes with prominent overrepresentation of genes implicated in contraction and migration. To explore potential disease relevance of our findings, we tested primary human lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and confirmed that YAP and TAZ combined knockdown reduced the expression of three cytoskeletal genes, ACTA2, CNN1, and TAGLN. We then compared the contribution of these genes, along with YAP and TAZ, to contractile function. Combined knockdown targeting YAP/TAZ was more effective than targeting any of the individual cytoskeletal genes in reducing contractile function. Together, our results demonstrate that YAP and TAZ combine to regulate a multigene program that is essential to fibroblast contractile function.
State-of-the-art beta-adrenoreceptor agonists for the treatment of asthma
Garzon-Siatoya, W. Tatiana, Carrillo‐Martin, Ismael, Gonzalez‐Estrada, Alexei , Chiarella, Sergio E , Gonzalez-Estrada, Alexei , Chiarella, Sergio E. , Garzon, Wendy

Mayo Clinic

Expert Opinion on Pharmacotherapy | November 10, 2021 | Volume: 23 | Issue: 2 | Pages: 243-254

10.1080/14656566.2021.1988074 | PMID 34753370 Get It